Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report

BACKGROUND: Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we reported in one case that a new symptom, Prurigo Nodularis (PN), developed during...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qingqing, Lyu, Jiajie, Gui, Yu, Yu, Shuling, Chen, Jiajie, Zhang, Haoxue, Liu, Shengxiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324148/
https://www.ncbi.nlm.nih.gov/pubmed/37408052
http://dx.doi.org/10.1186/s13223-023-00811-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324148/
https://www.ncbi.nlm.nih.gov/pubmed/37408052
http://dx.doi.org/10.1186/s13223-023-00811-5

Ejemplares similares